Merck misses profit estimates, forecasts larger hit to 2021 sales from pandemic
Reuters
Published Apr 29, 2021 06:45
Updated Apr 29, 2021 07:12
(Reuters) -Merck & Co Inc on Thursday missed estimates for first-quarter profit and forecast a bigger hit to 2021 sales than its previous estimate as the pandemic hurt demand for its drugs that need to be administered in a clinic.
Shares fell nearly 3% to $74.95 before the opening bell as the company also disclosed a roughly $600 million hit to first-quarter sales from the health crisis.
Merck now expects the COVID-19 pandemic will hurt its 2021 sales by 3%, up from 2% previously, as many of the company's drugs need to be administered at the doctor's office, which largely remained shut due to COVID-19 lockdowns.
A large blow was seen on sales of non-COVID-19 vaccines, including Gardasil, a vaccine to prevent cancers caused by the human papillomavirus virus, in the United States and Europe. Gardasil sales tumbled 16.4% to $917 million.
The company said it expected the impact to vaccines sales would persist during the first half of 2021, and that it would allocate doses of Gardasil to markets outside the United States to soften the blow.
Sales of blockbuster cancer drug Keytruda rose 18.7% to $3.90 billion, but missed Wall Street estimates of $3.98 billion.
Net earnings fell to $3.18 billion, or $1.25 per share, in the first-quarter ended March 31, from $3.22 billion, or $1.26 per share, a year earlier.
Excluding items, the company earned $1.40 per share, missing the average analyst estimate of $1.63, according to IBES data from Refinitiv.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.